Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WOPPPR: Neoadjuvant Radiation and Pembrolizumab in Recurrent Head and Neck Cancer
NCT07213934Phase 2Recruiting
- Sponsor
- University of Cincinnati
- Start
- Oct 2025
- Primary completion
- Dec 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Cincinnati. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07213934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213934.